Aldosteronism in heart failure

A proinflammatory/fibrogenic cardiac phenotype. Search for biomakers and potential drug targets

Karl Weber, Ivan Gerling, Mohammad F. Kiani, Ramareddy Guntaka, Yao Sun, Robert A. Ahokas, Arnold Postlethwaite, Kenneth J. Warrington

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi/nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory/fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.

Original languageEnglish (US)
Pages (from-to)505-516
Number of pages12
JournalCurrent Drug Targets
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2003

Fingerprint

Hyperaldosteronism
Heart Failure
Phenotype
Chemical activation
Pharmaceutical Preparations
Wasting Syndrome
Ventricular Dysfunction
Cachexia
Immune system
Angiotensins
Biomarkers
Renin-Angiotensin System
Medical problems
Aldosterone
Renin
Immune System
Blood Cells
Blood
Pumps
Hormones

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Aldosteronism in heart failure : A proinflammatory/fibrogenic cardiac phenotype. Search for biomakers and potential drug targets. / Weber, Karl; Gerling, Ivan; Kiani, Mohammad F.; Guntaka, Ramareddy; Sun, Yao; Ahokas, Robert A.; Postlethwaite, Arnold; Warrington, Kenneth J.

In: Current Drug Targets, Vol. 4, No. 6, 01.01.2003, p. 505-516.

Research output: Contribution to journalReview article

@article{710bd5fc6a2b4238aa2d5a7be6f3bdb2,
title = "Aldosteronism in heart failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomakers and potential drug targets",
abstract = "Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi/nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory/fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.",
author = "Karl Weber and Ivan Gerling and Kiani, {Mohammad F.} and Ramareddy Guntaka and Yao Sun and Ahokas, {Robert A.} and Arnold Postlethwaite and Warrington, {Kenneth J.}",
year = "2003",
month = "1",
day = "1",
doi = "10.2174/1389450033490948",
language = "English (US)",
volume = "4",
pages = "505--516",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Aldosteronism in heart failure

T2 - A proinflammatory/fibrogenic cardiac phenotype. Search for biomakers and potential drug targets

AU - Weber, Karl

AU - Gerling, Ivan

AU - Kiani, Mohammad F.

AU - Guntaka, Ramareddy

AU - Sun, Yao

AU - Ahokas, Robert A.

AU - Postlethwaite, Arnold

AU - Warrington, Kenneth J.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi/nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory/fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.

AB - Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi/nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory/fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.

UR - http://www.scopus.com/inward/record.url?scp=0038268569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038268569&partnerID=8YFLogxK

U2 - 10.2174/1389450033490948

DO - 10.2174/1389450033490948

M3 - Review article

VL - 4

SP - 505

EP - 516

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 6

ER -